Mer­ck takes home an FDA win for a Roger Perl­mut­ter fa­vorite, po­ten­tial­ly crack­ing open big mar­ket

With PD-(L)1 drug Keytru­da dom­i­nat­ing the port­fo­lio, erst­while Mer­ck R&D head Roger Perl­mut­ter at­tempt­ed to put the drug­mak­er on good foot­ing with a $2.2 bil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER